Shattuck Labs, Inc.(STTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

STTK Shattuck Labs, Inc.

Trading 05-16 12:11:11 EDT

8.04

-0.12

-1.46%

High8.48	Low8.04	Vol102.69K
Open8.28	D1 Closing8.16	Amplitude5.38%
Mkt Cap382.36M	Tradable Cap243.89M	Total Shares47.55M
T/O849.94K	T/O Rate0.34%	Tradable Shares30.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"STTK","market":"US","secType":"STK","nameCN":"Shattuck Labs, Inc.","latestPrice":8.041,"timestamp":1715875866210,"preClose":8.16,"halted":0,"volume":102693,"delay":0,"floatShares":30331155,"shares":47550872,"eps":-1.909221,"marketStatus":"Trading","change":-0.119,"latestTime":"05-16 12:11:11 EDT","open":8.28,"high":8.48,"low":8.041,"amount":849939.8468160001,"amplitude":0.053799,"askPrice":8.08,"askSize":297,"bidPrice":8.05,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.909221,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1715889600000},"marketStatusCode":2,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":8.16,"postHourTrading":{"tag":"盘后","latestPrice":8.0907,"preClose":8.16,"latestTime":"19:57 EDT","volume":656,"amount":5333.2445,"timestamp":1715817448425},"volumeRatio":0.37788},"requestUrl":"/m/hq/s/STTK/wiki","defaultTab":"wiki","newsList":[{"id":"2435398646","title":"TD Cowen Remains a Buy on Shattuck Labs (STTK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435398646","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435398646?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:16","pubTimestamp":1715771787,"startTime":"0","endTime":"0","summary":"In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Shattuck Labs (STTK – Research Report). The company’s shares closed...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-shattuck-labs-sttk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-shattuck-labs-sttk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435434455","title":"Buy Rating Affirmed: Shattuck Labs’ Promising Clinical Developments in HR-MDS and AML Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2435434455","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435434455?lang=en_us&edition=fundamental","pubTime":"2024-05-15 00:15","pubTimestamp":1715703324,"startTime":"0","endTime":"0","summary":"Shattuck Labs (STTK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-shattuck-labs-promising-clinical-developments-in-hr-mds-and-aml-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-shattuck-labs-promising-clinical-developments-in-hr-mds-and-aml-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435543602","title":"Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435543602","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435543602?lang=en_us&edition=fundamental","pubTime":"2024-05-15 00:10","pubTimestamp":1715703009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Shattuck Labs (STTK – Research Report) and Acrivon T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-shattuck-labs-sttk-and-acrivon-therapeutics-inc-acrv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-shattuck-labs-sttk-and-acrivon-therapeutics-inc-acrv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435840523","title":"Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2435840523","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2435840523?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:15","pubTimestamp":1715688900,"startTime":"0","endTime":"0","summary":"– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/14/2881907/0/en/Shattuck-Labs-to-Present-Additional-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myelodysplastic-Syndromes-HR-MDS.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432148475","title":"Shattuck Labs First Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2432148475","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432148475?lang=en_us&edition=fundamental","pubTime":"2024-05-04 20:01","pubTimestamp":1714824072,"startTime":"0","endTime":"0","summary":"NasdaqGS:STTK Earnings and Revenue History May 4th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates significantly. Earnings per share  also surpassed analyst estimates by 19%.Looking ahead, revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are up 1.8% from a week ago.You should learn about the   4 warning signs  we've spotted with Shattuck Labs .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-first-quarter-2024-120112977.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432193471","title":"Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2432193471","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2432193471?lang=en_us&edition=fundamental","pubTime":"2024-05-04 17:31","pubTimestamp":1714815110,"startTime":"0","endTime":"0","summary":"Revenue: Reported $1.115 million, significantly surpassing the estimated $0.23 million.Net Loss: Recorded at $18.5 million, above the estimated loss of $20.62 million.Earnings Per Share : Reported at -$0.37, better than the estimated -$0.45.Cash Reserves: Ended the quarter with $114.6 million in cash and investments, compared to $135.5 million the previous year.R&D Expenses: Slightly decreased to $16.3 million from $16.7 million in the same quarter last year.Financial Outlook: Cash and investments expected to fund operations into 2026, beyond results from Phase 1 clinical trials of SL-172154.On May 2, 2024, Shattuck Labs Inc , a trailblazer in bi-functional fusion protein technology, disclosed its financial outcomes for the first quarter ended March 31, 2024, through its 8-K filing. The company, known for its innovative approach in cancer and autoimmune disease treatments, reported a net loss of $18.5 million, or $0.37 per share, which notably improved from a net loss of $20.7 million,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-inc-sttk-reports-093150518.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432978794","title":"Shattuck Labs Inc    expected to post a loss of 41 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432978794","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432978794?lang=en_us&edition=fundamental","pubTime":"2024-05-03 19:35","pubTimestamp":1714736109,"startTime":"0","endTime":"0","summary":"* Shattuck Labs Inc     is expected to show a rise in quarterly revenue when it reports  results  for the period ending January 1 0001   * The Austin Texas-based  company is expected to report a 99.3%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432168934","title":"Buy Rating Affirmed for Shattuck Labs Ahead of Key Clinical Trial Updates on SL-172154","url":"https://stock-news.laohu8.com/highlight/detail?id=2432168934","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432168934?lang=en_us&edition=fundamental","pubTime":"2024-05-03 02:35","pubTimestamp":1714674947,"startTime":"0","endTime":"0","summary":"Shattuck Labs (STTK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-shattuck-labs-ahead-of-key-clinical-trial-updates-on-sl-172154?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-shattuck-labs-ahead-of-key-clinical-trial-updates-on-sl-172154?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432046986","title":"Shattuck Labs: Buy Rating Affirmed on Strong Q1 Financials and Promising Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2432046986","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432046986?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:35","pubTimestamp":1714664123,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Shattuck Labs (STTK – Research Report) and keeping the price target at $28...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/shattuck-labs-buy-rating-affirmed-on-strong-q1-financials-and-promising-clinical-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/shattuck-labs-buy-rating-affirmed-on-strong-q1-financials-and-promising-clinical-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432600387","title":"Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2432600387","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432600387?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:25","pubTimestamp":1714652710,"startTime":"0","endTime":"0","summary":"Shattuck Labs, Inc.  came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.28%. A quarter ago, it was expected that this company would post a loss of $0.51 per share when it actually produced a loss of $0.41, delivering a surprise of 19.61%.Shattuck Labs , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.12 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 457.50%. This compares to year-ago revenues of $0.06 million. The company has topped consensus revenue estimates three times over the last four quarters.Shattuck Labs shares have added about 52.3% since the beginning of the year versus the S&P 500's gain of 5.2%.While Shattuck Labs has outperformed the market so far this year, the question that","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-inc-sttk-reports-122510670.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432677441","title":"Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024,  Will Be Sufficient To Fund Its Operations Into 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2432677441","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432677441?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:14","pubTimestamp":1714652081,"startTime":"0","endTime":"0","summary":"Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024,  Will Be Sufficient To Fund Its Operations Into 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/05/38580735/shattuck-labs-cash-and-cash-equivalents-and-investments-of-114-6m-for-the-quarter-ended-march-31-","is_publish_highlight":false,"gpt_icon":0},{"id":"2432774496","title":"Shattuck Labs Q1 2024 GAAP EPS $(0.37) Beats $(0.46) Estimate, Sales $1.115M Beat $228.500K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2432774496","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432774496?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:11","pubTimestamp":1714651900,"startTime":"0","endTime":"0","summary":"Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 24.49 percent increase over losses of $(0.49) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38580575/shattuck-labs-q1-2024-gaap-eps-0-37-beats-0-46-estimate-sales-1-115m-beat-228-500k-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2432677600","title":"Shattuck Labs GAAP EPS of -$0.37, revenue of $1.11M","url":"https://stock-news.laohu8.com/highlight/detail?id=2432677600","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432677600?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:05","pubTimestamp":1714651519,"startTime":"0","endTime":"0","summary":"Shattuck Labs press release  (NASDAQ:STTK): Q1  GAAP EPS of -$0.37.\nRevenue of $1.11M.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098438-shattuck-labs-gaap-eps-of-0_37-revenue-of-1_11m","is_publish_highlight":false,"gpt_icon":0},{"id":"2432759446","title":"BRIEF-Shattuck Labs Q1 Net Income USD -18.504 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2432759446","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432759446?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:05","pubTimestamp":1714647945,"startTime":"0","endTime":"0","summary":"May 02 (Reuters) - Shattuck Labs Q1 basic EPS USD -0.37. * Q1 collaboration revenue USD 1.115 million * Q1 income from operations USD -20.044 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432757996","title":"Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2432757996","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432757996?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:05","pubTimestamp":1714647900,"startTime":"0","endTime":"0","summary":"- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant  Acute Myeloid Leukemia  patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology  2024 Annual Meeting in June –。- Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes  patients expected to initiate enrollment in the second quarter of 2024 –。- Presented preclinical data at the 2024 American Association for Cancer Research  Annual Meeting, demonstrating the potential therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy –。AUSTIN, TX and DURHAM, NC., May 02, 2024  -- Shattuck Labs, Inc.  , a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended Mar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GldEoY724_DyxYfLbsD3pA--~B/aD0yMDA7dz04NzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3182b35704decdc98925f01ce1a1b318","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GldEoY724_DyxYfLbsD3pA--~B/aD0yMDA7dz04NzE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3182b35704decdc98925f01ce1a1b318"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shattuck-labs-reports-first-quarter-110500519.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428597170","title":"Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),","url":"https://stock-news.laohu8.com/highlight/detail?id=2428597170","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2428597170?lang=en_us&edition=fundamental","pubTime":"2024-04-18 21:05","pubTimestamp":1713445536,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Shattuck Labs' stock price is sensitive to their trading actions. 53% of the business is held by the top 7 shareholders. To get a sense of who is truly in control of Shattuck Labs, Inc. , it is important to understand the ownership structure of the business. With 36% stake, institutions possess the maximum shares in the company. In other words, the group stands to gain the most  from their investment into the company.Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute.Let's take a closer look to see what the different types of shareholders can tell us about Shattuck Labs.What Does The Institutional Ownership Tell Us About Shattuck Labs?Researching institutional ownership is a good way to gauge and filter a stock's expected per","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/owning-36-shares-institutional-owners-130536975.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426788842","title":"Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426788842","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426788842?lang=en_us&edition=fundamental","pubTime":"2024-04-12 19:00","pubTimestamp":1712919636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Shattuck Labs (STTK – Research Report) and Verastem ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-shattuck-labs-sttk-and-verastem-vstm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-shattuck-labs-sttk-and-verastem-vstm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426417144","title":"Analysts Conflicted on These Healthcare Names: Shattuck Labs (STTK), Johnson & Johnson (JNJ) and Tilray (TLRY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2426417144","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426417144?lang=en_us&edition=fundamental","pubTime":"2024-04-11 00:10","pubTimestamp":1712765412,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Shattuck Labs (STTK – Research Report), Johnson & Johnson (JNJ – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-shattuck-labs-sttk-johnson-johnson-jnj-and-tilray-tlry?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-shattuck-labs-sttk-johnson-johnson-jnj-and-tilray-tlry?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shattucklabs.com","stockEarnings":[{"period":"1week","weight":-0.2221},{"period":"1month","weight":-0.1023},{"period":"3month","weight":-0.0923},{"period":"6month","weight":2.6923},{"period":"1year","weight":2.0792},{"period":"ytd","weight":0.1445}],"compareEarnings":[{"period":"1week","weight":0.0243},{"period":"1month","weight":0.0502},{"period":"3month","weight":0.0553},{"period":"6month","weight":0.1752},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.1146}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.223897},{"month":2,"riseRate":0.25,"avgChangeRate":-0.096809},{"month":3,"riseRate":0.25,"avgChangeRate":-0.198268},{"month":4,"riseRate":0.75,"avgChangeRate":0.095681},{"month":5,"riseRate":0,"avgChangeRate":-0.208243},{"month":6,"riseRate":1,"avgChangeRate":0.2047},{"month":7,"riseRate":0,"avgChangeRate":-0.161335},{"month":8,"riseRate":0,"avgChangeRate":-0.113737},{"month":9,"riseRate":0,"avgChangeRate":-0.167007},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.001908},{"month":11,"riseRate":0.5,"avgChangeRate":-0.023825},{"month":12,"riseRate":1,"avgChangeRate":0.775975}],"exchange":"NASDAQ","name":"Shattuck Labs, Inc.","nameEN":"Shattuck Labs, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shattuck Labs, Inc.(STTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shattuck Labs, Inc.(STTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shattuck Labs, Inc.,STTK,Shattuck Labs, Inc.股票,Shattuck Labs, Inc.股票老虎,Shattuck Labs, Inc.股票老虎国际,Shattuck Labs, Inc.行情,Shattuck Labs, Inc.股票行情,Shattuck Labs, Inc.股价,Shattuck Labs, Inc.股市,Shattuck Labs, Inc.股票价格,Shattuck Labs, Inc.股票交易,Shattuck Labs, Inc.股票购买,Shattuck Labs, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shattuck Labs, Inc.(STTK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shattuck Labs, Inc.(STTK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction